These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 36618081)
21. Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study). Hernández-Bernal F; Ricardo-Cobas MC; Martín-Bauta Y; Navarro-Rodríguez Z; Piñera-Martínez M; Quintana-Guerra J; Urrutia-Pérez K; Urrutia-Pérez K; Chávez-Chong CO; Azor-Hernández JL; Rodríguez-Reinoso JL; Lobaina-Lambert L; Colina-Ávila E; Bizet-Almeida J; Rodríguez-Nuviola J; Del Valle-Piñera S; Ramírez-Domínguez M; Tablada-Ferreiro E; Alonso-Valdés M; Lemos-Pérez G; Guillén-Nieto GE; Palenzuela-Díaz A; Noa-Romero E; Limonta-Fernández M; Fernández-Ávila JM; Ali-Mros NA; Del Toro-Lahera L; Remedios-Reyes R; Ayala-Ávila M; Muzio-González VL EClinicalMedicine; 2022 Apr; 46():101383. PubMed ID: 35434578 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Bravo L; Smolenov I; Han HH; Li P; Hosain R; Rockhold F; Clemens SAC; Roa C; Borja-Tabora C; Quinsaat A; Lopez P; López-Medina E; Brochado L; Hernández EA; Reynales H; Medina T; Velasquez H; Toloza LB; Rodriguez EJ; de Salazar DIM; Rodríguez CA; Sprinz E; Cerbino-Neto J; Luz KG; Schwarzbold AV; Paiva MS; Carlos J; Montellano MEB; de Los Reyes MRA; Yu CY; Alberto ER; Panaligan MM; Salvani-Bautista M; Buntinx E; Hites M; Martinot JB; Bhorat QE; Badat A; Baccarini C; Hu B; Jurgens J; Engelbrecht J; Ambrosino D; Richmond P; Siber G; Liang J; Clemens R Lancet; 2022 Jan; 399(10323):461-472. PubMed ID: 35065705 [TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Zhu FC; Guan XH; Li YH; Huang JY; Jiang T; Hou LH; Li JX; Yang BF; Wang L; Wang WJ; Wu SP; Wang Z; Wu XH; Xu JJ; Zhang Z; Jia SY; Wang BS; Hu Y; Liu JJ; Zhang J; Qian XA; Li Q; Pan HX; Jiang HD; Deng P; Gou JB; Wang XW; Wang XH; Chen W Lancet; 2020 Aug; 396(10249):479-488. PubMed ID: 32702299 [TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Zeng G; Wu Q; Pan H; Li M; Yang J; Wang L; Wu Z; Jiang D; Deng X; Chu K; Zheng W; Wang L; Lu W; Han B; Zhao Y; Zhu F; Yu H; Yin W Lancet Infect Dis; 2022 Apr; 22(4):483-495. PubMed ID: 34890537 [TBL] [Abstract][Full Text] [Related]
26. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM; Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274 [TBL] [Abstract][Full Text] [Related]
27. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Halperin SA; Ye L; MacKinnon-Cameron D; Smith B; Cahn PE; Ruiz-Palacios GM; Ikram A; Lanas F; Lourdes Guerrero M; Muñoz Navarro SR; Sued O; Lioznov DA; Dzutseva V; Parveen G; Zhu F; Leppan L; Langley JM; Barreto L; Gou J; Zhu T; Lancet; 2022 Jan; 399(10321):237-248. PubMed ID: 34953526 [TBL] [Abstract][Full Text] [Related]
28. Oral MucoRice-CTB vaccine for safety and microbiota-dependent immunogenicity in humans: a phase 1 randomised trial. Yuki Y; Nojima M; Hosono O; Tanaka H; Kimura Y; Satoh T; Imoto S; Uematsu S; Kurokawa S; Kashima K; Mejima M; Nakahashi-Ouchida R; Uchida Y; Marui T; Yoshikawa N; Nagamura F; Fujihashi K; Kiyono H Lancet Microbe; 2021 Sep; 2(9):e429-e440. PubMed ID: 35544149 [TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan. Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522 [TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311 [TBL] [Abstract][Full Text] [Related]
31. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ; Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136 [TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Ella R; Reddy S; Jogdand H; Sarangi V; Ganneru B; Prasad S; Das D; Raju D; Praturi U; Sapkal G; Yadav P; Reddy P; Verma S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Bhate A; Rai S; Panda S; Abraham P; Gupta N; Ella K; Bhargava B; Vadrevu KM Lancet Infect Dis; 2021 Jul; 21(7):950-961. PubMed ID: 33705727 [TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R; Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Tanriover MD; Doğanay HL; Akova M; Güner HR; Azap A; Akhan S; Köse Ş; Erdinç FŞ; Akalın EH; Tabak ÖF; Pullukçu H; Batum Ö; Şimşek Yavuz S; Turhan Ö; Yıldırmak MT; Köksal İ; Taşova Y; Korten V; Yılmaz G; Çelen MK; Altın S; Çelik İ; Bayındır Y; Karaoğlan İ; Yılmaz A; Özkul A; Gür H; Unal S; Lancet; 2021 Jul; 398(10296):213-222. PubMed ID: 34246358 [TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial. Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368 [TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP; Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591 [TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Xia S; Zhang Y; Wang Y; Wang H; Yang Y; Gao GF; Tan W; Wu G; Xu M; Lou Z; Huang W; Xu W; Huang B; Wang W; Zhang W; Li N; Xie Z; Zhu X; Ding L; You W; Zhao Y; Zhao J; Huang L; Shi X; Yang Y; Xu G; Wang W; Liu P; Ma M; Qiao Y; Zhao S; Chai J; Li Q; Fu H; Xu Y; Zheng X; Guo W; Yang X Lancet Infect Dis; 2022 Feb; 22(2):196-208. PubMed ID: 34536349 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. Dai L; Gao L; Tao L; Hadinegoro SR; Erkin M; Ying Z; He P; Girsang RT; Vergara H; Akram J; Satari HI; Khaliq T; Sughra U; Celi AP; Li F; Li Y; Jiang Z; Dalimova D; Tuychiev J; Turdikulova S; Ikram A; Flores Lastra N; Ding F; Suhardono M; Fadlyana E; Yan J; Hu Z; Li C; Abdurakhmonov IY; Gao GF; N Engl J Med; 2022 Jun; 386(22):2097-2111. PubMed ID: 35507481 [TBL] [Abstract][Full Text] [Related]
39. Comparative Immune Response after Vaccination with SOBERANA Pérez-Nicado R; Massa C; Rodríguez-Noda LM; Müller A; Puga-Gómez R; Ricardo-Delgado Y; Paredes-Moreno B; Rodríguez-González M; García-Ferrer M; Palmero-Álvarez I; Garcés-Hechavarría A; Rivera DG; Valdés-Balbín Y; Vérez-Bencomo V; García-Rivera D; Seliger B Vaccines (Basel); 2023 Oct; 11(11):. PubMed ID: 38005968 [TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials. Ozdarendeli A; Sezer Z; Pavel STI; Inal A; Yetiskin H; Kaplan B; Uygut MA; Bayram A; Mazicioglu M; Unuvar GK; Yuce ZT; Aydin G; Aslan AF; Kaya RK; Koc RC; Ates I; Kara A Vaccine; 2023 Jan; 41(2):380-390. PubMed ID: 36460536 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]